A Phase II Study of Nivolumab Monotherapy in Patients With Relapsed/Refractory Hodgkin Lymphoma Fit for Autologous Stem Cell Transplant Who Fail to Reach Complete Metabolic Remission After First or Second Line Salvage Therapy
Latest Information Update: 20 Sep 2024
Price :
$35 *
At a glance
- Drugs Nivolumab (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- Acronyms ANIMATE
- 09 May 2024 Planned End Date changed from 11 Dec 2025 to 28 Feb 2026.
- 09 Feb 2023 Planned primary completion date changed from 11 Dec 2022 to 1 Mar 2023.
- 09 Nov 2022 Status changed from recruiting to active, no longer recruiting.